Publications by authors named "Abdulhamid Bazarbachi"
Cytokines in hematopoietic cell transplantation and related cellular therapies.
Best Pract Res Clin Haematol
December 2024
Cytokines are pleiotropic molecules involved in hematopoiesis, immune responses, infections, and inflammation. They play critical roles in hematopoietic cell transplantation (HCT) and immune effector cell (IEC) therapies, mediating both therapeutic and adverse effects. Thus, cytokines contribute to the immunopathology of graft-versus-host disease (GVHD), cytokine release syndrome (CRS), and immune effector cell-associated neurotoxicity syndrome (ICANS).
View Article and Find Full Text PDFArticle Synopsis
- * This subtype of MM does not indicate a high-risk phenotype, yet shows reduced response to treatments like proteasome inhibitors and immunomodulatory drugs, possibly due to lower immunoglobulin production.
- * The distinct dependence on Bcl-2 makes t(11;14)-MM sensitive to the drug venetoclax, and further understanding of its morphological and genomic characteristics could improve predictions of treatment responses.
Article Synopsis
- * An analysis of data from 3649 patients showed that ATG had worse outcomes in terms of nonrelapse mortality and overall survival compared to PTCy alone; however, the combination of PTCy and ATG significantly reduced GVHD occurrences without affecting other transplant outcomes.
- * The authors suggest that while ATG monotherapy is less effective, the PTCy and ATG combination may establish a new
Article Synopsis
- Adult T-cell leukemia/lymphoma (ATLL) has poor treatment outcomes, but allogeneic stem-cell transplantation (allo-SCT) shows promise, despite limited data.
- In a study involving 100 ATLL patients, 17 underwent allo-SCT with notable improvements in 3-year progression-free survival (31%) and overall survival (35%), compared to autologous SCT (ASCT) which had a higher relapse incidence.
- Factors such as achieving a complete response, a high Karnofsky score, and ethnicity influenced survival outcomes, indicating that allo-SCT may offer long-term survival benefits for select ATLL patients.
Introduction/background: Azacytidine (AZA) has been used as a promising treatment for relapse after allogeneic transplantation. A clear benefit has been demonstrated when treating patients with a reduced disease burden, thus a prophylactic and preemptive approach to these patients has emerged.
Materials And Methods: We retrospectively analyzed patients with myeloid malignancies treated with azacytidine in the posttransplantation setting between September 2013 and April 2018 in a single tertiary care hospital.
The efficacy of anti-thymocyte globulin (ATG) as prophylaxis for graft-versus-host disease (GVHD) has been investigated by many clinical studies over the past decade, including some randomized controlled trials. Intriguingly, although ATG is commonly used as prophylaxis for GVHD, there is still controversy about the optimal dose of ATG for prophylaxis of GVHD after allogeneic hematopoietic cell transplantation (allo-HCT). Indeed, the dose and formulation of ATG, as well as the degree of clinical benefit, has varied among studies, which makes it difficult to fully determine the clinical benefit of ATG.
View Article and Find Full Text PDFObjectives: This retrospective study analyzed the impact of early cyclosporine A (CsA) initiation (day -3) on the risk of acute graft-vs-host disease (aGvHD) after haploidentical hematopoietic cell transplantation (Haplo-HCT) using post-transplant cyclophosphamide.
Methods: Sixty-one consecutives patients who underwent Haplo-HCT were analyzed.
Results: At day +180, the cumulative incidences of grade II-IV and grade III-IV aGvHD were 39% and 18%, respectively.
Article Synopsis
- Iron overload (IOL) in non-transfusion-dependent thalassemia (NTDT) is primarily caused by increased intestinal iron absorption and worsens with age.
- Low serum hepcidin levels lead to excess iron absorption and release from macrophages, resulting in liver iron loading and various health issues.
- Effective diagnosis and monitoring of body iron levels are crucial, and iron chelation therapy (ICT) is key to managing IOL and reducing complications in NTDT patients.